Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: A cross-sectional population survey

Thrombosis and Haemostasis

Volumn 86, Issue 2, 2001, Pages 550-556

  Lowe, G D O ^a   Upton, M N ^a   Rumley, A ^a   McConnachie, A ^a   O'Reilly, D St J ^a   Watt, G C M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

C reactive protein; Coagulation; Fibrinolysis; Menopause; Oestrogens

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; C REACTIVE PROTEIN; CHOLESTEROL; ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LIVER PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; HYPOTHESIS; INFLAMMATION; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOSIS;

EID: 0034907754     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616085     Document Type: Article

References (38)

1. The epidemiology of coronary heart disease and estrogen replacement in post-menopausal women
2. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease
3. Post-menopausal hormone replacement therapy and cardiovascular disease
4. Hormone replacement therapy and haemostatic function
5. Risk of venous thromboembolism in users of hormone replacement therapy
6. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
7. Prospective study of exogenous hormones and risk of pulmonary embolism in women
8. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
9. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in Southern Europe
10. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study
11. Activated protein C resistance and the FV: R506Q mutation in a random population sample
12. The metabolic consequences of treating post-menopausal women with non-oral hormone replacement therapy
13. Effects of hormone-replacement therapy on fibrinolysis in post-menopausal women
14. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women
15. Haemostatic risk factors for arterial and venous thrombosis
16. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults-the Midspan family study surveys of parents and offspring
17. Effects of lipids and lipoproteins on thrombosis and rheology
18. Lipid-thrombosis interface
19. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies
20. Cardiorespiratory disease in men and women in urban Scotland: Baseline characteristics of the Renfrew/Paisley (Midspan) study population
21. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease
22. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use
23. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
24. Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study
25. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: Relationships to hormone replacement therapy
26. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women
27. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
28. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
29. Coagulation, fibrinolysis and hormone replacement therapy
30. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C
31. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity
32. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
33. Hormone replacement therapy, inflammation, and hemostasis in elderly women
34. Estriol: A potent regulator of TNF and IL-6 expression in a murine model of endotoxemia
35. Characterization of an interaction between protein C and ceruloplasmin
36. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
37. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
38. Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analyses of prospective studies of coronary heart disease